marked.bio

Company

FutureGen Biopharmaceutical

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

2 of 2 trials shown

  1. A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

    Not yet recruiting Phase 3 FutureGen Biopharmaceutical Started 2026Primary completion 2030-06 NCT07383922

    FG-M108nab-paclitaxelgemcitabine

    …ical tissue for CLDN18.2 testing, with central laboratory testing confirming tumor tissue CLDN18.2 positive (defined as ≥40% of tumor cells with CLDN18.2 membrane staining ≥2+ by central l…

    Claudin 18.2 expressionPancreatic Cancer

  2. A Phase I/II Study of FG-M108 Plus FG-B901 in Advanced CLDN18.2-Positive Solid Tumors

    Not yet recruiting Phase 1/2 FutureGen Biopharmaceutical Started 2026Primary completion 2028-08 NCT07704866

    FG-B901FG-M108

    CLDN18.2 positive (defined as ≥10% of tumor cells showing membrane staining ≥1+ by central laborat…

    Claudin 18.2 expressionClaudin 18.2, Solid Tumor Malignancies